Literature DB >> 11399232

Clinical protocol. An open-label, phase I, dose-escalation study of tumor necrosis factor-alpha (TNFerade Biologic) gene transfer with radiation therapy for locally advanced, recurrent, or metastatic solid tumors.

A Sharma, S Mani, N Hanna, C Guha, B Vikram, R R Weichselbaum, J Sparano, B Sood, D Lee, W Regine, M Muhodin, J Valentino, J Herman, P Desimone, S Arnold, J Carrico, A K Rockich, J Warner-Carpenter, M Barton-Baxter.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2001        PMID： 11399232     DOI： 10.1089/104303401750214320

Source DB:  PubMed          Journal:  Hum Gene Ther        ISSN： 1043-0342            Impact factor:   5.695


× No keyword cloud information.
  5 in total

1.  A pilot feasibility study of TNFerade™ biologic with capecitabine and radiation therapy followed by surgical resection for the treatment of rectal cancer.

Authors:  Deborah Citrin; Kevin Camphausen; Bradford J Wood; Martha Quezado; John Denobile; James F Pingpank; Richard E Royal; H Richard Alexander; Geoffrey Seidel; Seth M Steinberg; Yvonne Shuttack; Steven K Libutti
Journal:  Oncology       Date:  2011-03-25       Impact factor: 2.935

2.  A phase I dose escalation study of Ad GV.EGR.TNF.11D (TNFerade™ Biologic) with concurrent chemoradiotherapy in patients with recurrent head and neck cancer undergoing reirradiation.

Authors:  T Y Seiwert; T Darga; D Haraf; E A Blair; K Stenson; E E W Cohen; J K Salama; V Villaflor; M E Witt; M W Lingen; R R Weichselbaum; E E Vokes
Journal:  Ann Oncol       Date:  2012-10-26       Impact factor: 32.976

Review 3.  Radiotherapy in Combination With Cytokine Treatment.

Authors:  Ondrej Palata; Nada Hradilova Podzimkova; Eva Nedvedova; Alexandra Umprecht; Lenka Sadilkova; Lenka Palova Jelinkova; Radek Spisek; Irena Adkins
Journal:  Front Oncol       Date:  2019-05-22       Impact factor: 6.244

4.  Endoscopic ultrasound-guided oncologic therapy for pancreatic cancer.

Authors:  Rei Suzuki; Atsushi Irisawa; Manoop S Bhutani
Journal:  Diagn Ther Endosc       Date:  2013-02-24

Review 5.  TNFerade, an innovative cancer immunotherapeutic.

Authors:  Arunava Kali
Journal:  Indian J Pharmacol       Date:  2015 Sep-Oct       Impact factor: 1.200
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.